These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9552949)

  • 21. Heart Protection Study.
    Metcalfe RS; Dawson S; Milne RJ
    Lancet; 2003 Feb; 361(9356):528; author reply 529-30. PubMed ID: 12583966
    [No Abstract]   [Full Text] [Related]  

  • 22. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholestanol and survival with simvastatin. More data are needed.
    Wallis EJ; Williamson R; Ramsay LE; Yeo WW; Jackson PR
    BMJ; 1998 Oct; 317(7167):1252-3. PubMed ID: 9794879
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum lipid pattern as severity indicator of angiographically assessed coronary artery disease.
    Uccella R; Donnini P; Franzetti I; Gaiazzi M
    Artery; 1993; 20(6):346-60. PubMed ID: 8010890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
    Zou Y; Hu D; Yang X; Xu Z; Cui L; Liu X; Wei Y; Gao M
    Chin Med J (Engl); 2003 Jun; 116(6):853-6. PubMed ID: 12877794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk reduction strategies in coronary artery disease.
    Gibson TM; Ratts T
    J La State Med Soc; 2001 Jun; 153(6):312-9. PubMed ID: 11480382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
    Michelena HI; Osorio LA; Citkowitz E
    Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation of non-cholesterol sterols to coronary risk factors and carotid intima-media thickness: the Cardiovascular Risk in Young Finns Study.
    Miettinen TA; Gylling H; Hallikainen M; Juonala M; Räsänen L; Viikari J; Raitakari OT
    Atherosclerosis; 2010 Apr; 209(2):592-7. PubMed ID: 19963215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
    Stevermer JJ; Meadows SE
    J Fam Pract; 2002 Oct; 51(10):893. PubMed ID: 12401164
    [No Abstract]   [Full Text] [Related]  

  • 30. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antioxidant versus lipid-altering therapy--some answers, more questions.
    Freedman JE
    N Engl J Med; 2001 Nov; 345(22):1636-7. PubMed ID: 11757512
    [No Abstract]   [Full Text] [Related]  

  • 34. HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.
    Frick MH; Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Mänttäri M
    Drugs; 1990; 40 Suppl 1():7-12. PubMed ID: 2289410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
    Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 37. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study.
    Muntner P; Lee F; Astor BC
    Am J Med Sci; 2011 Mar; 341(3):173-80. PubMed ID: 21042169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [For coronary disease patients is certain: the lower the LDL the better].
    MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
    [No Abstract]   [Full Text] [Related]  

  • 39. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart Protection Study.
    Poli A; Catapano A
    Lancet; 2003 Feb; 361(9356):528; author reply 529-30. PubMed ID: 12583967
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.